A Single-Arm, Open-Label, Phase I Study of GK01 for Advanced Solid Tumor
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: GK01 Injection
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-01
- Target Recruit Count
- 15
- Registration Number
- NCT06954558
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
Phase 2
Not yet recruiting
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-04-30
- Target Recruit Count
- 33
- Registration Number
- NCT06951997
A Phase II Study on Ivonescimab Plus AG Regimen as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
- First Posted Date
- 2025-04-25
- Last Posted Date
- 2025-04-25
- Target Recruit Count
- 30
- Registration Number
- NCT06944106
- Locations
- 🇨🇳
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China
Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC
Phase 2
Recruiting
- Conditions
- NSCLC (Non-small Cell Lung Cancer)
- Interventions
- Drug: Neoadjuvant Cryoablation Combined with Tislelizumab and ChemotherapyProcedure: Surgery
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Target Recruit Count
- 38
- Registration Number
- NCT06939127
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer
Phase 2
Not yet recruiting
- Conditions
- Pancreatic Cancer, Adult
- Interventions
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Target Recruit Count
- 48
- Registration Number
- NCT06938503
QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
Phase 2
Recruiting
- Conditions
- Endometrial AdenocarcinomaEndometrial Cancer
- Interventions
- Drug: QL1706 combined with chemotherapy ± Bevacizumab
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Target Recruit Count
- 30
- Registration Number
- NCT06917092
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Phase 1
Recruiting
- Conditions
- Peripheral T-cell LymphomaCutaneous T-cell Lymphoma (CTCL)NHL (Non-Hodgkin Lymphoma)
- Interventions
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-04-06
- Target Recruit Count
- 24
- Registration Number
- NCT06914037
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy
Phase 2
Not yet recruiting
- Conditions
- Lung Cancer, Small CellLimited-stage Small Cell Lung Cancer (LS-SCLC)
- Interventions
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-04-25
- Target Recruit Count
- 30
- Registration Number
- NCT06914050
Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC
Phase 2
Not yet recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: Firmonertinib combined with Carboplatin/Cisplatin and Pemetrexed
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-03-21
- Target Recruit Count
- 31
- Registration Number
- NCT06890182
A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
Phase 2
Recruiting
- Conditions
- Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-25
- Target Recruit Count
- 138
- Registration Number
- NCT06878625
- Locations
- 🇨🇳
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China
© Copyright 2025. All Rights Reserved by MedPath